Rasagiline
- Generic Name
- Rasagiline
- Brand Names
- Azilect, Rasagiline Mylan, Rasagiline ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13N
- CAS Number
- 136236-51-6
- Unique Ingredient Identifier
- 003N66TS6T
- Background
Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
- Indication
For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
- Associated Conditions
- Parkinson's Disease (PD)
- Associated Therapies
- -
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Yunxia Wang, MD
- Target Recruit Count
- 36
- Registration Number
- NCT01232738
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 839
- Registration Number
- NCT01215227
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
- Conditions
- Interventions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 52
- Registration Number
- NCT01192503
- Locations
- 🇺🇸
University of Pennsylvania Sleep Center, Philadelphia, Pennsylvania, United States
🇺🇸SUNY- Buffalo Jacobs Neurological Institute, Buffalo, New York, United States
🇺🇸Medical College of Georgia Movements Disorders Program, Augusta, Georgia, United States
Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy
- Conditions
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Prof. Dr. Stefan Lorenzl
- Target Recruit Count
- 44
- Registration Number
- NCT01187888
- Locations
- 🇩🇪
Department of Neurology and Palliative Care Klinikum der Universität München (Hospital of the University of Munich), München, Germany
Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 1
- Registration Number
- NCT01178047
- Locations
- 🇨🇭
University Hospital, Neurology, Zurich, ZH, Switzerland
🇨🇭Neurocentro, Lugano, Lugano, Switzerland
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 30
- Registration Number
- NCT01168596
- Locations
- 🇺🇸
Shands and University of Florida Medical Plaza, Gainesville, Florida, United States
🇺🇸University of Colorado Anschutz outpatient Pavilion, Aurora, Colorado, United States
🇺🇸Cleveland Clinic Center for Neurological Restoration, Cleveland, Ohio, United States
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
- Conditions
- Interventions
- First Posted Date
- 2010-01-25
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Lundbeck Italia S.p.A.
- Target Recruit Count
- 121
- Registration Number
- NCT01055379
- Locations
- 🇮🇹
IT001, Naples, Italy
🇮🇹IT008, Rome, Italy
🇮🇹IT015, Torino, Italy
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Teva Neuroscience, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT01049984
- Locations
- 🇺🇸
Teva Investigational Site 21, Medford, Oregon, United States
🇺🇸Teva Investigational Site 31, Charlotte, North Carolina, United States
🇺🇸Teva Investigational Site 09, Richmond, Virginia, United States
Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Qualissima
- Target Recruit Count
- 112
- Registration Number
- NCT01048229
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- The Parkinson's Institute
- Target Recruit Count
- 36
- Registration Number
- NCT01007630
- Locations
- 🇺🇸
The Parkinson's Institute, Sunnyvale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.